Literature DB >> 27179547

Identification of Two Novel LAMP2 Gene Mutations in Danon Disease.

Beáta Csányi1, Anca Popoiu2, Lidia Hategan1, Zoltán Hegedűs3, Viktória Nagy1, Katalin Rácz4, Márta Hőgye1, László Sághy1, Béla Iványi5, Miklós Csanády1, Tamás Forster1, Róbert Sepp6.   

Abstract

BACKGROUND: Danon disease is a rare X-linked inherited disorder characterized by massive left ventricular hypertrophy, skeletal muscle dystrophy, and mental retardation. The disease is caused by mutations in the LAMP2 gene encoding for lysosome-associated membrane protein-2.
METHODS: Two young male patients with hypertrophic cardiomyopathy, characterized by marked, concentric left ventricular hypertrophy, elevated levels of creatine kinase, and manifest limb-girdle muscular dystrophy in 1 case, were investigated. Genetic screening included direct sequencing of the whole coding sequence of the LAMP2 gene.
RESULTS: Genetic analysis identified 2 novel LAMP2 gene mutations. In Family A, a G-A transition (c.962G > A) leading to a nonsense mutation at codon 321 (p.Trp321Ter), and in Family B, a one-nucleotide insertion (c.973insC) leading to a full frame-shift (p.Pro324+24X) was detected in exon 8 of the LAMP2 gene. Family screening identified 8 mutation carriers, with 4 nonpenetrant cases and 3 additional, probably affected family members without DNA diagnosis. The cardiac phenotype was hypertrophic cardiomyopathy in all cases, including female mutation carriers. Five disease-related deaths occurred in the families, at an average age of 33 ± 16 years, which was clearly lower in male than in female patients (28 ± 7 vs 42 ± 25 years). A high prevalence of arrhythmias or conduction abnormalities was also observed.
CONCLUSIONS: The reported 2 novel LAMP2 gene mutation carrier families, one of them being one of the largest reported to date, highlight the malignant clinical course of Danon disease, characterized by a high rate of disease-related death at an early age and a high prevalence of arrhythmias or conduction abnormalities.
Copyright © 2016 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27179547     DOI: 10.1016/j.cjca.2016.02.071

Source DB:  PubMed          Journal:  Can J Cardiol        ISSN: 0828-282X            Impact factor:   5.223


  4 in total

1.  Prevalence and clinical characteristics of Danon disease among patients with left ventricular hypertrophy and concomitant electrocardiographic preexcitation.

Authors:  Yang Liu; Xin Chen; Feng Wang; Yingcong Liang; Hai Deng; Hongtao Liao; Qianhuan Zhang; Bin Zhang; Xianzhang Zhan; Xianhong Fang; Michael Shehata; Xunzhang Wang; Yumei Xue; Shulin Wu
Journal:  Mol Genet Genomic Med       Date:  2019-03-30       Impact factor: 2.183

Review 2.  Danon disease: a case report and literature review.

Authors:  Jiamin Xu; Zhu Li; Yihai Liu; Xinlin Zhang; Fengnan Niu; Hongyan Zheng; Lian Wang; Lina Kang; Kun Wang; Biao Xu
Journal:  Diagn Pathol       Date:  2021-05-01       Impact factor: 3.196

3.  A Mild Version of Danon Disease Caused by a Newly Recognized Mutation in the Lysosome-associated Membrane Protein-2 Gene.

Authors:  Htoo Kyaw; Fatima Shaik; Aung Naing Lin; Meir Shinnar
Journal:  Cureus       Date:  2018-02-04

4.  Lamp2 inhibits epithelial-mesenchymal transition by suppressing Snail expression in HCC.

Authors:  Hao Zheng; Yuan Yang; Chen Ye; Peng-Peng Li; Zhen-Guang Wang; Hao Xing; Hao Ren; Wei-Ping Zhou
Journal:  Oncotarget       Date:  2018-07-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.